Abzena Supplies Clinical Trial Material for Angiex's Phase 1 Study of First-in-Class TM4SF1-Directed ADC

09 August 2024

Abzena Supports Angiex’s Phase 1 Study of TM4SF1-Directed ADC Therapy

Angiex has secured clinical trial materials from Abzena for its Phase 1 study of AGX101, a groundbreaking TM4SF1-targeted antibody-drug conjugate (ADC). AGX101 represents a novel approach to cancer therapy by targeting the blood vessels within tumors, offering potential new treatment options for patients with aggressive cancers. The Phase 1 study aims to evaluate the safety and preliminary efficacy of this first-in-class therapy.

Drug Development & Delivery, a leading publication in pharmaceutical research and innovation, covered this critical partnership. Known for its in-depth analysis of drug development processes and industry trends, Drug Development & Delivery highlighted the significance of Abzena’s role in providing the necessary resources for Angiex’s trial and underscored the importance of reliable partnerships in advancing novel therapies toward clinical success.

About Angiex

Angiex, Inc. is a privately held biotech whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by leading scientific experts in angiogenesis, vascular biology, and oncology. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus of cells in the tumor environment. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. Angiex’s lead product, AGX101, with its novel and differentiated mechanisms of action, represents a first-in-class drug with potential to address high unmet medical needs.

Get in touch